Special Issue "Pharmacology and Medicinal Value of Flowering Plant in the Treatment of Non-communicable Diseases"
Deadline for manuscript submissions: closed (31 May 2023) | Viewed by 3392
Interests: ethnobotany; ethnopharmacology; anti-cancer; organoids models; anti-inflammatory; gastrointestinal protective agents
Interests: antioxidants; cytotoxicity; antitumor action; cancer and prospection of bioactive molecules of natural and synthetic origin
Recent estimates shows that non-communicable diseases (NCDs) are responsible for the majority of deaths worldwide. NCDs are responsible for the deaths of approximately 41 million people each year, equivalent of 71% of all global deaths. Of these NCDs, cancer is one of the four groups of diseases that account for over 80% of all premature NCD deaths. In fact, it is the second most important NCD, causing the loss of 9.3 million lives on a yearly basis worldwide, representing a challenging situation, particularly regarding its pharmacological treatments. Recently, evidence from several scientific reports has thrown light on molecular and cellular mechanisms linking inflammation and cancer. Chronic inflammation, being one of the risk factors, is implicated in many environmental causes of cancer. In particular, pro-tumorigenic inflammation promotes cancer by blocking anti-tumor immunity, and drives tumor microenvironment towards a more tumor-permissive state.
Historically, plants are important therapeutic and preventive agents that have been used for millennia. In addition, it represents one of the natural arsenal of medicines that can be effectively harnessed to treat, prevent and manage inflammation, oxidative stress and tumor developments. There is growing volume of scientific evidence that plants or products derived from them might have a role to play in suppressing acute and chronic inflammations, effect sometimes attributed to their in vivo antioxidants properties. Another interesting fact about flowering plants is the use of some of species as supplements or “nutraceuticals” with promising preclinical and epidemiological studies pointing to their efficacy and safety. These facts have caused increased interest from many stakeholders, including the scientific community. However, in many cases, these plants lack rigorous scientific proof, and anecdotal evidence is presented.
This Special Issue is dedicated to highlighting important medicinal flowering plants with substantial pre-clinical and clinical evidence for their efficacy in the prevention or treatments of inflammation and cancer/antitumor activities. In this context, we invite investigators to submit both original research and review articles that explore these aspects, including preclinical and in human studies.
Dr. Sikiru Olaitan Balogun
Dr. Edson Lucas Dos Santos
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- medicinal plants
- non-communicable diseases
- secondary metabolites